Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.874
Filtrer
1.
Bull Exp Biol Med ; 177(1): 44-46, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38955851

RÉSUMÉ

The acute toxicity of chlorophyllin and trolox upon intraperitoneal injection of their solutions was studied in male ICR (CD-1) mice. The LD50 of chlorophyllin was found to be 633±37.2 µg/g body weight, which is lower than the LD50 of established radioprotectors. Trolox is technically non-toxic under the conditions of our study. The results obtained highlight the need for a detailed study of the radioprotective properties of trolox and chlorophyllin.


Sujet(s)
Chlorophyllides , Chromanes , Souris de lignée ICR , Radioprotecteurs , Animaux , Mâle , Radioprotecteurs/pharmacologie , Chlorophyllides/pharmacologie , Chromanes/pharmacologie , Souris , Dose létale 50 , Antioxydants/pharmacologie , Injections péritoneales
2.
J Chem Inf Model ; 64(12): 4877-4896, 2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-38856697

RÉSUMÉ

Programmed death-ligand 1 (PD-L1) has emerged as a promising therapeutic target for various cancers due to its crucial role in promoting tumor immune evasion. Here, we report a novel class of chroman-like small-molecule PD-L1 inhibitors exhibiting significant activity in inhibiting the PD-1/PD-L1 interaction. Employing a "ring-close" strategy for conformational restriction, we have achieved compound C27, which demonstrates superior PD-1/PD-L1 inhibitory activity compared to the positive control. Molecular dynamics simulation and binding free energy calculation predict that (R)-C27 with inhibitory activity surpassed (S)-C27. The experimental results from bioassay and X-ray structural analysis corroborate these findings. All these results collectively indicate that (R)-C27 is a promising lead compound deserving further exploration.


Sujet(s)
Antigène CD274 , Chromanes , Conception de médicament , Récepteur-1 de mort cellulaire programmée , Antigène CD274/antagonistes et inhibiteurs , Antigène CD274/métabolisme , Récepteur-1 de mort cellulaire programmée/antagonistes et inhibiteurs , Récepteur-1 de mort cellulaire programmée/métabolisme , Humains , Chromanes/composition chimique , Chromanes/pharmacologie , Simulation de dynamique moléculaire
3.
J Med Chem ; 67(13): 11435-11449, 2024 Jul 11.
Article de Anglais | MEDLINE | ID: mdl-38889119

RÉSUMÉ

Enhancing the selectivity of alpha2-adrenoceptor (α2A-AR) agonists remains an unresolved issue. Herein, we reported the design of an α2A-AR agonist using the conformation constraint method, beginning with medetomidine. The structure-activity relationship indicated that the 8-substituent of chromane derivatives exerted the most pronounced effect on α2A-AR agonistic activity. Compounds A9 and B9 were identified as the most promising, exhibiting EC50 values of 0.78 and 0.23 nM, respectively. Their selectivity indexes surpassed dexmedetomidine (DMED) by 10-80 fold. In vivo studies demonstrated that both A9 and B9 dose-dependently increased the loss of righting reflex in mice, with ED50 values of 1.54 and 0.138 mg/kg, respectively. Binding mode calculations and mutation studies suggested the indispensability of the hydrogen bond between ASP1283.32 and α2A-AR agonist. In particular, A9 and B9 showed no dual reverse pharmacological effect, a characteristic exhibited by DMED in α2A-AR activation.


Sujet(s)
Agonistes des récepteurs alpha-2 adrénergiques , Chromanes , Conception de médicament , Récepteurs alpha-2 adrénergiques , Animaux , Récepteurs alpha-2 adrénergiques/métabolisme , Chromanes/pharmacologie , Chromanes/composition chimique , Chromanes/synthèse chimique , Relation structure-activité , Souris , Agonistes des récepteurs alpha-2 adrénergiques/pharmacologie , Agonistes des récepteurs alpha-2 adrénergiques/composition chimique , Humains , Conformation moléculaire , Simulation de docking moléculaire , Mâle
4.
Sci Rep ; 14(1): 13315, 2024 06 10.
Article de Anglais | MEDLINE | ID: mdl-38858439

RÉSUMÉ

Exposure to high, marginally lethal doses or higher of ionizing radiation, either intentional or accidental, results in injury to various organs. Currently, there is only a limited number of safe and effective radiation countermeasures approved by US Food and Drug Administration for such injuries. These approved agents are effective for only the hematopoietic component of the acute radiation syndrome and must be administered only after the exposure event: currently, there is no FDA-approved agent that can be used prophylactically. The nutraceutical, gamma-tocotrienol (GT3) has been found to be a promising radioprotector of such exposure-related injuries, especially those of a hematopoietic nature, when tested in either rodents or nonhuman primates. We investigated the nature of injuries and the possible protective effects of GT3 within select organ systems/tissues caused by both non-lethal level (4.0 Gy), as well as potentially lethal level (5.8 Gy) of ionizing radiation, delivered as total-body or partial-body exposure. Results indicated that the most severe, dose-dependent injuries occurred within those organ systems with strong self-renewing capacities (e.g., the lymphohematopoietic and gastrointestinal systems), while in other tissues (e.g., liver, kidney, lung) endowed with less self-renewal, the pathologies noted tended to be less pronounced and less dependent on the level of exposure dose or on the applied exposure regimen. The prophylactic use of the test nutraceutical, GT3, appeared to limit the extent of irradiation-associated pathology within blood forming tissues and, to some extent, within the small intestine of the gastrointestinal tract. No distinct, global pattern of bodily protection was noted with the agent's use, although a hint of a possible radioprotective benefit was suggested not only by a lessening of apparent injury within select organ systems, but also by way of noting the lack of early onset of moribundity within select GT3-treated animals.


Sujet(s)
Compléments alimentaires , Radioprotecteurs , Animaux , Radioprotecteurs/pharmacologie , Vitamine E/pharmacologie , Vitamine E/analogues et dérivés , Syndrome d'irradiation aigu/prévention et contrôle , Syndrome d'irradiation aigu/traitement médicamenteux , Syndrome d'irradiation aigu/anatomopathologie , Chromanes/pharmacologie , Mâle , Lésions radiques expérimentales/prévention et contrôle , Lésions radiques expérimentales/anatomopathologie , Macaca mulatta , Foie/effets des médicaments et des substances chimiques , Foie/effets des radiations , Foie/anatomopathologie
5.
Bioorg Med Chem Lett ; 108: 129789, 2024 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-38729318

RÉSUMÉ

Receptors are proteinous macromolecules which remain in the apo form under normal/unliganded conditions. As the ligand approaches, there are specific stereo-chemical changes in the apo form of the receptor as per the stereochemistry of a ligand. Accordingly, a series of substituted dimethyl-chroman-based stereochemically flexible and constrained Tamoxifen analogs were synthesized as anti-breast cancer agents. The synthesized compounds 19a-e, 20a-e, 21, and 22a-e, showed significant antiproliferative activity against estrogen receptor-positive (ER+, MCF-7) and negative (ER-, MDA MB-231) cells within IC50 value 8.5-25.0 µM. Amongst all, four potential molecules viz 19b, 19e, 22a, and 22c, were evaluated for their effect on the cell division cycle and apoptosis of ER+ and ER- cancer cells (MCF-7 & MDA MB-231cells), which showed that these compounds possessed antiproliferative activity through triggering apoptosis. In-silico docking experiments elucidated the possible affinity of compounds with estrogen receptors-α and -ß.


Sujet(s)
Antinéoplasiques , Apoptose , Tumeurs du sein , Prolifération cellulaire , Tests de criblage d'agents antitumoraux , Humains , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/anatomopathologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Stéréoisomérie , Relation structure-activité , Lignée cellulaire tumorale , Apoptose/effets des médicaments et des substances chimiques , Chromanes/pharmacologie , Chromanes/synthèse chimique , Chromanes/composition chimique , Simulation de docking moléculaire , Récepteur alpha des oestrogènes/métabolisme , Récepteur alpha des oestrogènes/antagonistes et inhibiteurs , Femelle , Structure moléculaire , Cellules MCF-7 , Relation dose-effet des médicaments , Tamoxifène/pharmacologie , Tamoxifène/synthèse chimique , Tamoxifène/composition chimique
6.
Chem Biodivers ; 21(7): e202400587, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38718104

RÉSUMÉ

A library of new chroman-4-one based 1,2,3-triazole analogues were synthesized involving a series of condensation, cyclization, Suzuki coupling and copper catalysed click chemistry protocols. The newly synthesized compounds 8a-l were screened for their invitro antioxidant and anti-inflammatory activities by employing Ascorbic acid and Diclofenac as reference drugs respectively. The compound without any substituent on benzyl ring (8a), compound with -Cl substituent in para position of benzyl ring (8i), and compound with ethoxy substituent in para position of benzyl ring (8k) exhibited potent antioxidant and anti-inflammatory activities with higher percentage of inhibition. To understand their binding affinities, molecular docking study of these three compounds performed against NADPH oxidase with presented outstanding docking scores and promising binding interactions like H-bond and hydrophobic.


Sujet(s)
Antioxydants , Simulation de docking moléculaire , Triazoles , Triazoles/composition chimique , Triazoles/pharmacologie , Triazoles/synthèse chimique , Antioxydants/pharmacologie , Antioxydants/composition chimique , Antioxydants/synthèse chimique , Relation structure-activité , NADPH oxidase/métabolisme , NADPH oxidase/antagonistes et inhibiteurs , Animaux , Anti-inflammatoires non stéroïdiens/pharmacologie , Anti-inflammatoires non stéroïdiens/composition chimique , Anti-inflammatoires non stéroïdiens/synthèse chimique , Chromanes/composition chimique , Chromanes/pharmacologie , Chromanes/synthèse chimique , Anti-inflammatoires/composition chimique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/synthèse chimique , Structure moléculaire , Relation dose-effet des médicaments , Picrates/antagonistes et inhibiteurs
7.
Mol Nutr Food Res ; 68(10): e2300657, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38698718

RÉSUMÉ

SCOPE: Tocomonoenols (T1) are little-known vitamin E derivatives naturally occurring in foods. Limited knowledge exists regarding the cellular uptake and metabolism of α-tocomonoenol (αT1) and none about that of γ-tocomonoenol (γT1). METHODS AND RESULTS: The study investigates the cytotoxicity, uptake, and metabolism of αT1 and γT1 in HepG2 cells compared to the α- and γ-tocopherols (T) and -tocotrienols (T3). None of the studied tocochromanols are cytotoxic up to 100 µmol L-1. The uptake of the γ-congeners is significantly higher than that of the corresponding α-forms, whereas no significant differences are observed based on the degree of saturation of the sidechain. Carboxymethylbutyl-hydroxychromans (CMBHC) are the predominant short-chain metabolites of all tocochromanols and conversion is higher for γT1 than αT1 as well as for the γ-congeners of T and T3. The rate of metabolism increases with the number of double bonds in the sidechain. The rate of metabolic conversion of the T1 is more similar to tocopherols than to that of the tocotrienols. CONCLUSION: This is the first evidence that both αT1 and γT1 follow the same sidechain degradation pathway and exert similar rates of metabolism than tocopherols. Therefore, investigation into the biological activities of tocomonoenols is warranted.


Sujet(s)
Chromanes , Vitamine E , Humains , Cellules HepG2 , Chromanes/pharmacologie , Vitamine E/pharmacologie , Vitamine E/analogues et dérivés , Vitamine E/métabolisme , Vitamine E/pharmacocinétique , gamma-Tocophérol/métabolisme , gamma-Tocophérol/pharmacologie , Tocotriénols/pharmacologie , Tocotriénols/métabolisme , Tocotriénols/pharmacocinétique , Survie cellulaire/effets des médicaments et des substances chimiques , alpha-Tocophérol/pharmacologie , alpha-Tocophérol/métabolisme , alpha-Tocophérol/analogues et dérivés
8.
Int J Mol Sci ; 23(24)2022 Dec 18.
Article de Anglais | MEDLINE | ID: mdl-36555814

RÉSUMÉ

Radiation exposure causes acute damage to hematopoietic and immune cells. To date, there are no radioprotectors available to mitigate hematopoietic injury after radiation exposure. Gamma-tocotrienol (GT3) has demonstrated promising radioprotective efficacy in the mouse and nonhuman primate (NHP) models. We determined GT3-mediated hematopoietic recovery in total-body irradiated (TBI) NHPs. Sixteen rhesus macaques divided into two groups received either vehicle or GT3, 24 h prior to TBI. Four animals in each treatment group were exposed to either 4 or 5.8 Gy TBI. Flow cytometry was used to immunophenotype the bone marrow (BM) lymphoid cell populations, while clonogenic ability of hematopoietic stem cells (HSCs) was assessed by colony forming unit (CFU) assays on day 8 prior to irradiation and days 2, 7, 14, and 30 post-irradiation. Both radiation doses showed significant changes in the frequencies of B and T-cell subsets, including the self-renewable capacity of HSCs. Importantly, GT3 accelerated the recovery in CD34+ cells, increased HSC function as shown by improved recovery of CFU-granulocyte macrophages (CFU-GM) and burst-forming units erythroid (B-FUE), and aided the recovery of circulating neutrophils and platelets. These data elucidate the role of GT3 in hematopoietic recovery, which should be explored as a potential medical countermeasure to mitigate radiation-induced injury to the hematopoietic system.


Sujet(s)
Cellules souches hématopoïétiques , Vitamine E , Souris , Animaux , Macaca mulatta , Vitamine E/pharmacologie , Chromanes/pharmacologie , Irradiation corporelle totale
9.
Contrast Media Mol Imaging ; 2022: 7445042, 2022.
Article de Anglais | MEDLINE | ID: mdl-36072638

RÉSUMÉ

The effect of the TGF-ß pathway-based pituitary tumor of rats on the GH3 cell line after intervention with different concentrations of troglitazone (TGZ) is explored. The CH3 cell line of 24 clean male SD rats with pituitary adenoma is selected. The cells are divided into a blank contrast set and an experimental set. The experimental set is divided into different TGZ concentration sets, including 1 × 10-3 TGZ set, 1 × 10-4 TGZ set, and 1 × 10-5 TGZ set. The cell proliferation is detected by the CCK-8 method, the protein expressions of CD147, TGF-ß1, and MMP-9 are detected by the western blot method, and the relative mRNA expressions of CD147, TGF-ß1, and MMP-9 are detected by the qRT-PCR method. The expression levels of CD147, TGF-ß1, and MMP-9 in CH3 cells of pituitary adenoma rats are notoriously lower, while the expression of CD147, TGF-31, and MMP-9 could be reduced by TGZ acting on the GH3 cell line. The specific mechanism of action of this effect on the invasive ability of GH3 cell lines is multifaceted, suggesting that peroxisome proliferator activator-receptor (PPAR-γ) agonists have good clinical application prospects in tumor therapy and can provide new targets and approaches for tumor drug therapy.


Sujet(s)
Tumeurs de l'hypophyse , Thiazolidinediones , Animaux , Lignée cellulaire , Chromanes/pharmacologie , Mâle , Matrix metalloproteinase 9 , Tumeurs de l'hypophyse/génétique , Rats , Rat Sprague-Dawley , Thiazolidinediones/pharmacologie , Facteur de croissance transformant bêta , Facteur de croissance transformant bêta-1 , Troglitazone
10.
Biol Pharm Bull ; 45(3): 276-283, 2022.
Article de Anglais | MEDLINE | ID: mdl-35228393

RÉSUMÉ

Lung cancer is the leading cause of cancer-related deaths worldwide. Troglitazone (TGZ), a peroxisome proliferator-activated receptor gamma (PPARγ) ligand, is a potential antitumor agent. However, the action mechanism of TGZ in lung adenocarcinoma cells has not been completely elucidated. To assess this mechanism and the anticancer effects of TGZ in human lung adenocarcinoma cell lines (A549 and H1975), we investigated the involvement of PPARγ, apoptosis, the mitogen-activated protein kinase (MAPK) pathway, protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, and autophagy. Cell viability was measured using fluorescence-based assays. Apoptotic cells were detected by Hoechst 33342 and Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double staining; protein expression was detected by Western blotting. TGZ inhibited cell proliferation in a dose-dependent manner in both cell lines, and the effect was not suppressed by a PPARγ inhibitor. Additionally, TGZ increased apoptotic cell number and upregulated p38 and c-Jun N-terminal kinase (JNK) phosphorylation; however, p38 and JNK inhibitors did not block TGZ-mediated inhibition of cell proliferation in either cell line. TGZ also upregulated extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, whereas an ERK1/2 inhibitor enhanced TGZ-mediated cytotoxicity in A549 cells. Additionally, TGZ increased LC3-II expression, and chloroquine (an autophagy inhibitor) attenuated TGZ-mediated inhibition of cell proliferation. These findings suggest that TGZ-induced inhibition of cell proliferation is PPARγ independent. TGZ-mediated inhibition of cell proliferation was accompanied by apoptosis and independent of the MAPK signaling pathway. These results suggest that TGZ inhibits cell proliferation through autophagy-induced cytotoxicity. This study demonstrated that chemotherapy using TGZ may be effective for lung adenocarcinoma.


Sujet(s)
Adénocarcinome pulmonaire , Thiazolidinediones , Adénocarcinome pulmonaire/traitement médicamenteux , Apoptose , Autophagie , Lignée cellulaire , Lignée cellulaire tumorale , Prolifération cellulaire , Chromanes/pharmacologie , Humains , Thiazolidinediones/pharmacologie , Troglitazone/pharmacologie
11.
Am J Physiol Renal Physiol ; 322(2): F197-F207, 2022 02 01.
Article de Anglais | MEDLINE | ID: mdl-35001664

RÉSUMÉ

KV7 channels, the voltage-gated K+ channels encoded by KCNQ genes, mediate heterogeneous vascular responses in rodents. Postnatal changes in the functional expression of KV7 channels have been reported in rodent saphenous arteries, but their physiological function in the neonatal renal vascular bed is unclear. Here, we report that, unlike adult pigs, only KCNQ1 (KV7.1) out of the five members of KCNQ genes was detected in neonatal pig renal microvessels. KCNQ1 is present in fetal pig kidneys as early as day 50 of gestation, and the level of expression remains the same up to postnatal day 21. Activation of renal vascular smooth muscle cell (SMC) KV7.1 stimulated whole cell currents, inhibited by HMR1556 (HMR), a selective KV7.1 blocker. HMR did not change the steady-state diameter of isolated renal microvessels. Similarly, intrarenal artery infusion of HMR did not alter mean arterial pressure, renal blood flow, and renal vascular resistance in the pigs. An ∼20 mmHg reduction in mean arterial pressure evoked effective autoregulation of renal blood flow, which HMR inhibited. We conclude that 1) the expression of KCNQ isoforms in porcine renal microvessels is dependent on kidney maturation, 2) KV7.1 is functionally expressed in neonatal pig renal vascular SMCs, 3) a decrease in arterial pressure up to 20 mmHg induces renal autoregulation in neonatal pigs, and 4) SMC KV7.1 does not control basal renal vascular tone but contributes to neonatal renal autoregulation triggered by a step decrease in arterial pressure.NEW & NOTEWORTHY KV7.1 is present in fetal pig kidneys as early as day 50 of gestation, and the level of expression remains the same up to postnatal day 21. KV7.1 is functionally expressed in neonatal pig renal vascular smooth muscle cells (SMCs). A decrease in arterial pressure up to 20 mmHg induces renal autoregulation in neonatal pigs. Although SMC KV7.1 does not control basal renal vascular resistance, its inhibition blunts neonatal renal autoregulation engendered by a step decrease in arterial pressure.


Sujet(s)
Pression artérielle/effets des médicaments et des substances chimiques , Chromanes/pharmacologie , Canal potassique KCNQ1/antagonistes et inhibiteurs , Rein/vascularisation , Muscles lisses vasculaires/effets des médicaments et des substances chimiques , Myocytes du muscle lisse/effets des médicaments et des substances chimiques , Inhibiteurs des canaux potassiques/pharmacologie , Circulation rénale/effets des médicaments et des substances chimiques , Sulfonamides/pharmacologie , Vasodilatation/effets des médicaments et des substances chimiques , Animaux , Animaux nouveau-nés , Régulation de l'expression des gènes au cours du développement , Âge gestationnel , Homéostasie , Canal potassique KCNQ1/génétique , Canal potassique KCNQ1/métabolisme , Microvaisseaux/effets des médicaments et des substances chimiques , Microvaisseaux/métabolisme , Muscles lisses vasculaires/métabolisme , Myocytes du muscle lisse/métabolisme , Transduction du signal , Sus scrofa
12.
Future Med Chem ; 14(5): 325-342, 2022 03.
Article de Anglais | MEDLINE | ID: mdl-34985322

RÉSUMÉ

Aim: Literature reports suggest spirochromanone derivatives exhibit anticancer activity. Methodology: The authors designed and synthesized 18 spirochromanone derivatives (Csp 1-18). The compounds were characterized and evaluated for anticancer activity against human breast cancer (MCF-7) and murine melanoma (B16F10) cell lines. Results: The anticancer activity ranged from 4.34 to 29.31 µm. The most potent compounds, Csp 12 and Csp 18, were less toxic against the human embryonic kidney (HEK-293) cell line and ∼ two/∼fourfold selective toward MCF-7 than B16F10 in comparison to the reference, BG-45. Csp 12 caused 28.6% total apoptosis, leading to significant cytotoxicity, and arrested the G2 phase of the cell cycle in B16F10 cells. A molecular docking study of Csp 12 exhibited effective binding at the active site of the epidermal growth factor receptor kinase domain. Conclusion: This study highlights the importance of spirochromanones as anticancer agents.


Sujet(s)
Antinéoplasiques/synthèse chimique , Chromanes/composition chimique , Conception de médicament , Spiranes/composition chimique , Animaux , Antinéoplasiques/métabolisme , Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Sites de fixation , Domaine catalytique , Lignée cellulaire tumorale , Chromanes/métabolisme , Chromanes/pharmacologie , Tests de criblage d'agents antitumoraux , Récepteurs ErbB/antagonistes et inhibiteurs , Récepteurs ErbB/métabolisme , Points de contrôle de la phase G2 du cycle cellulaire/effets des médicaments et des substances chimiques , Humains , Souris , Simulation de docking moléculaire , Relation structure-activité
13.
Bioorg Med Chem ; 57: 116629, 2022 03 01.
Article de Anglais | MEDLINE | ID: mdl-35091169

RÉSUMÉ

Malaria is a prevalent and lethal disease. The fast emergence and spread of resistance to current therapies is a major concern and the development of a novel line of therapy that could overcome, the problem of drug resistance, is imperative. Screening of a set of compounds with drug/natural product-based sub-structural motifs led to the identification of spirocyclic chroman-4-one 1 with promising antimalarial activity against the chloroquine-resistant Dd2 and chloroquine-sensitive 3D7 strains of the parasite. Extensive structure-activity and structure-property relationship studies were conducted to identify the essential features necessary for its activity and properties.


Sujet(s)
Antipaludiques/pharmacologie , Chromanes/pharmacologie , Paludisme/traitement médicamenteux , Plasmodium/effets des médicaments et des substances chimiques , Spiranes/pharmacologie , Antipaludiques/synthèse chimique , Antipaludiques/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Chromanes/synthèse chimique , Chromanes/composition chimique , Cristallographie aux rayons X , Relation dose-effet des médicaments , Cellules HepG2 , Humains , Modèles moléculaires , Structure moléculaire , Tests de sensibilité parasitaire , Spiranes/synthèse chimique , Spiranes/composition chimique , Relation structure-activité
14.
Methods Mol Biol ; 2343: 247-258, 2022.
Article de Anglais | MEDLINE | ID: mdl-34473328

RÉSUMÉ

A high global prevalence of diabetes and its implications on the heart in vivo and in vitro tools have been pursued to alleviate the complications of high glucose. This chapter oulines the methods used for maintaining H9C2 cardiomyoblasts in vitro and for stimulating hyperglycemic situation. In addition, we present a method to assess cellular GLUT-4 expression using qRT-PCR. This cellular model also allows us to examine the therapeutic approach of an antioxidant, Trolox, for upregulating GLUT-4 and uptake of glucose under hyperglycemic condition.


Sujet(s)
Antioxydants , Diabète , Myocarde , Réaction de polymérisation en chaîne , Antioxydants/pharmacologie , Chromanes/pharmacologie , Glucose , Transporteur de glucose de type 4/analyse , Humains , Myocarde/cytologie , Réaction de polymérisation en chaîne/méthodes
15.
Food Funct ; 13(1): 398-410, 2022 Jan 04.
Article de Anglais | MEDLINE | ID: mdl-34908071

RÉSUMÉ

γ-Tocotrienol (γ-T3), an isoprenoid phytochemical, has shown the promotion of osteoblast proliferation and differentiation in our previous study. In this study, its underlying mechanism was investigated through regulating the Wnt/ß-catenin signaling pathway in MC3T3-E1 cells. Comparative experiment results showed that γ-T3, not α-tocopherol (α-TOC) increased more significantly the viability and differentiation in MC3T3-E1 cells. After that, the cells were incubated with 10 mM LiCl, or 4 µM γ-T3 with or without 1 µM XAV-939. γ-T3 at 4 µM stimulated the Wnt/ß-catenin signaling pathway by increasing the expression and nuclear accumulation of ß-catenin, and the expressions of their downstream factors, such as cyclin-D1, c-Myc, BMP2 and BMP-4 in MC3T3-E1 cells. γ-T3 not only upregulated the viability, induced G0/G1 to the S phase, and promoted the expressions of PCNA (Proliferating Cell Nuclear Antigen) and Ki-67, but also increased ALP activity and the expressions of ON, OPN and OCN. Moreover, the effects of γ-T3 on the MC3T3-E1 cells resembled the actions of LiCl, an activator of the Wnt/ß-catenin signaling pathway. Notably, all these effects of γ-T3 on the MC3T3-E1 cells were completely blocked by the Wnt/ß-catenin signaling pathway inhibitor XAV-939. Our data demonstrated that γ-T3 can target ß-catenin to enhance the Wnt/ß-catenin signaling pathway, which led to increased expressions of the downstream cell proliferation and cell cycle-associated (cyclin D1 and c-myc), and cell differentiation-associated (BMP-2 and BMP-4) target genes, and ultimately promoted MC3T3-E1 cell proliferation and differentiation. Therefore, γ-T3 may be a potential agent to prevent and reverse osteoporosis due to its safety and powerful abilities of osteogenesis.


Sujet(s)
Différenciation cellulaire/effets des médicaments et des substances chimiques , Chromanes/pharmacologie , Vitamine E/analogues et dérivés , Voie de signalisation Wnt/effets des médicaments et des substances chimiques , Animaux , Lignée cellulaire , Prolifération cellulaire/effets des médicaments et des substances chimiques , Souris , Ostéoblastes/effets des médicaments et des substances chimiques , Vitamine E/pharmacologie
16.
Int J Mol Sci ; 22(23)2021 Nov 24.
Article de Anglais | MEDLINE | ID: mdl-34884479

RÉSUMÉ

Ischemia-induced mitochondrial dysfunction and ATP depletion in the kidney result in disruption of primary functions and acute injury of the kidney. This study tested whether γ-tocotrienol (GTT), a member of the vitamin E family, protects mitochondrial function, reduces ATP deficits, and improves renal functions and survival after ischemia/reperfusion injury. Vehicle or GTT (200 mg/kg) were administered to mice 12 h before bilateral kidney ischemia, and endpoints were assessed at different timepoints of reperfusion. GTT treatment reduced decreases in state 3 respiration and accelerated recovery of this function after ischemia. GTT prevented decreases in activities of complexes I and III of the respiratory chain, and blocked ischemia-induced decreases in F0F1-ATPase activity and ATP content in renal cortical tissue. GTT improved renal morphology at 72 h after ischemia, reduced numbers of necrotic proximal tubular and inflammatory cells, and enhanced tubular regeneration. GTT treatment ameliorated increases in plasma creatinine levels and accelerated recovery of creatinine levels after ischemia. Lastly, 89% of mice receiving GTT and 70% of those receiving vehicle survived ischemia. Conclusions: Our data show novel observations that GTT administration improves mitochondrial respiration, prevents ATP deficits, promotes tubular regeneration, ameliorates decreases in renal functions, and increases survival after acute kidney injury in mice.


Sujet(s)
Atteinte rénale aigüe/traitement médicamenteux , Chromanes/pharmacologie , Transport d'électrons/effets des médicaments et des substances chimiques , Métabolisme énergétique , Mitochondries/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , Lésion d'ischémie-reperfusion/traitement médicamenteux , Vitamine E/analogues et dérivés , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/métabolisme , Atteinte rénale aigüe/anatomopathologie , Adénosine triphosphate/métabolisme , Animaux , Mâle , Souris , Souris de lignée C57BL , Mitochondries/anatomopathologie , Lésion d'ischémie-reperfusion/étiologie , Lésion d'ischémie-reperfusion/métabolisme , Lésion d'ischémie-reperfusion/anatomopathologie , Vitamine E/pharmacologie
17.
J Nat Prod ; 84(11): 2953-2960, 2021 11 26.
Article de Anglais | MEDLINE | ID: mdl-34787427

RÉSUMÉ

Penicisteckins A-D (1-4), two pairs of atropodiastereomeric biaryl-type hetero- and homodimeric bis-isochromans with 7,5'- and 7,7'-linkages and a pair of atropodiastereomeric 2-(isochroman-5-yl)-1,4-benzoquinone derivatives [penicisteckins E (5) and F (6)], were isolated from the Penicillium steckii HNNU-5B18. Their structures including the absolute configuration were determined by extensive spectroscopic and single-crystal X-ray diffraction analysis and TDDFT-ECD calculations. Both the bis-isochromans and the isochroman/1,4-benzoquinone conjugates represent novel biaryl scaffolds containing both central and axial chirality elements. The monomer anserinone B (8) exhibited potent antibacterial activities against Staphylococcus aureus ATCC 29213 and methicillin-resistant Staphylococcus aureus with minimal inhibition concentration values ranging from 2 to 8 µg mL-1. Plausible biosynthetic pathways of 1-6 are proposed, which suggest how the absolute configurations of the isolates were established during the biosynthetic scheme.


Sujet(s)
Antibactériens/isolement et purification , Chromanes/isolement et purification , Penicillium/métabolisme , Antibactériens/composition chimique , Antibactériens/pharmacologie , Voies de biosynthèse , Chromanes/composition chimique , Chromanes/pharmacologie , Staphylococcus aureus/effets des médicaments et des substances chimiques
18.
Molecules ; 26(21)2021 Nov 05.
Article de Anglais | MEDLINE | ID: mdl-34771113

RÉSUMÉ

Phytochemical investigation of the ethanol extract of underground parts of Iris tenuifolia Pall. afforded five new compounds; an unusual macrolide termed moniristenulide (1), 5-methoxy-6,7-methylenedioxy-4-O-2'-cycloflavan (2), 5,7,2',3'-tetrahydroxyflavanone (3), 5-hydroxy-6,7-dimethoxyisoflavone-2'-O-ß-d-glucopyranoside (9), 5,2',3'-dihydroxy-6,7-dimethoxyisoflavone (10), along with seven known compounds (4-8, 11-12). The structures of all purified compounds were established by analysis of 1D and 2D NMR spectroscopy and HR-ESI-MS. The antimicrobial activity of the compounds 1-3, 5, 9, and 10 was investigated using the agar diffusion method against fungi, Gram-positive and Gram-negative bacteria. In consequence, new compound 3 was found to possess the highest antibacterial activity against Enterococcus faecalis VRE and Mycobacterium vaccae. Cell proliferation and cytotoxicity tests were also applied on all isolated compounds and plant crude extract in vitro with the result of potent inhibitory effect against leukemia cells. In particular, the newly discovered isoflavone 10 was active against both of the leukemia cells K-562 and THP-1 while 4-6 of the flavanone type compounds were active against only THP-1.


Sujet(s)
Anti-infectieux/pharmacologie , Antinéoplasiques/pharmacologie , Chromanes/pharmacologie , Iris (plante)/composition chimique , Extraits de plantes/pharmacologie , Anti-infectieux/composition chimique , Antinéoplasiques/composition chimique , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Chromanes/composition chimique , Relation dose-effet des médicaments , Humains , Spectroscopie par résonance magnétique , Conformation moléculaire , Structure moléculaire , Extraits de plantes/composition chimique
19.
Int J Mol Sci ; 22(17)2021 Aug 31.
Article de Anglais | MEDLINE | ID: mdl-34502402

RÉSUMÉ

Microglial functioning depends on Ca2+ signaling. By using Ca2+ sensitive fluorescence dye, we studied how inhibition of mitochondrial respiration changed spontaneous Ca2+ signals in soma of microglial cells from 5-7-day-old rats grown under normoxic and mild-hypoxic conditions. In microglia under normoxic conditions, metformin or rotenone elevated the rate and the amplitude of Ca2+ signals 10-15 min after drug application. Addition of cyclosporin A, a blocker of mitochondrial permeability transition pore (mPTP), antioxidant trolox, or inositol 1,4,5-trisphosphate receptor (IP3R) blocker caffeine in the presence of rotenone reduced the elevated rate and the amplitude of the signals implying sensitivity to reactive oxygen species (ROS), and involvement of mitochondrial mPTP together with IP3R. Microglial cells exposed to mild hypoxic conditions for 24 h showed elevated rate and increased amplitude of Ca2+ signals. Application of metformin or rotenone but not phenformin before mild hypoxia reduced this elevated rate. Thus, metformin and rotenone had the opposing fast action in normoxia after 10-15 min and the slow action during 24 h mild-hypoxia implying activation of different signaling pathways. The slow action of metformin through inhibition of complex I could stabilize Ca2+ homeostasis after mild hypoxia and could be important for reduction of ischemia-induced microglial activation.


Sujet(s)
Signalisation calcique/effets des médicaments et des substances chimiques , Metformine/pharmacologie , Animaux , Caféine/pharmacologie , Signalisation calcique/physiologie , Chromanes/pharmacologie , Ciclosporine/pharmacologie , Complexe I de la chaîne respiratoire/métabolisme , Femelle , Hypoxie/génétique , Hypoxie/métabolisme , Mâle , Metformine/métabolisme , Microglie/effets des médicaments et des substances chimiques , Microglie/métabolisme , Mitochondries/métabolisme , Protéines de transport de la membrane mitochondriale/métabolisme , Neurones/métabolisme , Culture de cellules primaires , Rats , Espèces réactives de l'oxygène/métabolisme , Roténone/pharmacologie
20.
Naunyn Schmiedebergs Arch Pharmacol ; 394(11): 2289-2307, 2021 11.
Article de Anglais | MEDLINE | ID: mdl-34468817

RÉSUMÉ

At present, thiamine deficiency (TD) is managed with administration of high doses of thiamine. Even so, severe and permanent neurological disorders can occur in recurrent episodes of TD. In this study, we used a murine model to assess the efficacy of TD recovery treatments using thiamine with or without additional administration of the antioxidant Trolox or the anti-inflammatory dimethyl sulfoxide (DMSO) after a single or recurrent episode of TD. TD was induced for 9 days with deficient chow and pyrithiamine, and the recovery period was 7 days with standard amounts of chow and thiamine, Trolox, and/or DMSO. After these periods, we evaluated behavior, histopathology, and ERK1/2 modulation in the brain. Deficient animals showed reductions in locomotor activity, motor coordination, and spatial memory. Morphologically, after a single episode of TD and recovery, deficient mice showed neuronal vacuolization in the dorsal thalamus and, after two episodes, a reduction in neuronal cell number. These effects were attenuated or reversed by the recovery treatments, mainly in the treatments with thiamine associated with Trolox or DMSO. Deficient animals showed a strong increase in ERK1/2 phosphorylation in the thalamus, hippocampus, and cerebral cortex after one deficiency episode and recovery. Interestingly, after recurrent TD and recovery, ERK1/2 phosphorylation remained high only in the deficient mice treated with thiamine and/or Trolox or thiamine with DMSO. Our data suggest that a protocol for TD treatment with thiamine in conjunction with Trolox or DMSO enhances the recovery of animals and possibly minimizes the late neurological sequelae.


Sujet(s)
Chromanes/pharmacologie , Diméthylsulfoxyde/pharmacologie , Carence en thiamine/traitement médicamenteux , Thiamine/administration et posologie , Animaux , Anti-inflammatoires/administration et posologie , Anti-inflammatoires/pharmacologie , Antioxydants/administration et posologie , Antioxydants/pharmacologie , Comportement animal/effets des médicaments et des substances chimiques , Chromanes/administration et posologie , Diméthylsulfoxyde/administration et posologie , Modèles animaux de maladie humaine , Locomotion/effets des médicaments et des substances chimiques , Mâle , Souris , Récidive , Mémoire spatiale/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...